Skip to main content
SpringerLink
Log in

Psoriatic Arthritis: A Dermatologist’s Perspective

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Psoriatic arthritis (PsA) is a common, destructive arthritis that may manifest in more than one-third of psoriasis patients. Dermatologists are in a unique position to diagnose PsA early, and to start prompt, effective treatment. Such early intervention with biological agents such as tumor necrosis factor alpha antagonists, which appear to hold particular promise in the long-term management of PsA, may significantly reduce morbidity, improve quality of life and substantially reduce the economic (patient and societal) burden of PsA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58: 851–64

    Article  PubMed  Google Scholar 

  2. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52: 1–19

    Article  PubMed  Google Scholar 

  3. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573.e1–573.e13

    Article  Google Scholar 

  4. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–73

    Article  PubMed  Google Scholar 

  5. Husni ME, Meyer KH, Cohen DS, et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581–7

    Article  PubMed  Google Scholar 

  6. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)–an analysis of 220 patients. Q J Med 1987; 62: 127–41

    PubMed  CAS  Google Scholar 

  7. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245–50

    Article  PubMed  CAS  Google Scholar 

  8. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280–4

    PubMed  CAS  Google Scholar 

  9. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000; 27: 1247–50

    PubMed  CAS  Google Scholar 

  10. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868–72

    CAS  Google Scholar 

  11. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264–72

    Article  PubMed  CAS  Google Scholar 

  12. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33: 712–21

    PubMed  CAS  Google Scholar 

  13. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279–89

    Article  PubMed  CAS  Google Scholar 

  14. Mease P, Gladman D, Ritchlin C, et al. Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial [abstract P2865]. J Am Acad Dermatol 2006; 54 (Suppl. 1): AB214

    Google Scholar 

  15. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150–7

    Article  PubMed  CAS  Google Scholar 

  16. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66: 498–505

    Article  PubMed  CAS  Google Scholar 

  17. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54: 1638–45

    Article  PubMed  CAS  Google Scholar 

  18. Kavanaugh A, Mease P, Krueger G, et al. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL Study [abstract 671]. 72nd Annual Scientific Meeting of the American College of Rheumatology and the 43rd Annual Meeting of the Association of Rheumatology; 2008 October 24–29, 2008; San Francisco, California, USA; 2008

    Google Scholar 

  19. Papp KA, Caro I, Leung HM, et al. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007; 11: 57–66

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Editorial assistance for the preparation of this manuscript was provided by Stephanie Blick of inScience Communications. This assistance was funded by Pfizer. The author has served as a speaker for Amgen and Abbott.

Author information

Authors and Affiliations

  1. Dermatology Consultants of Broward, 603 N. Flamingo Rd Ste 350, Pembroke Pines, 33028, Florida, USA

    Robert Alan Snyder

  2. Miller School of Medicine, University of Miami, Miami, Florida, USA

    Robert Alan Snyder

Authors
  1. Robert Alan Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Snyder, R.A. Psoriatic Arthritis: A Dermatologist’s Perspective. AM J Clin Dermatol 11 (Suppl 1), 19–22 (2010). https://doi.org/10.2165/1153416-S0-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1153416-S0-000000000-00000

Keywords

Search

Navigation